Dapirolizumab pegol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Dapirolizumab pegol Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Dapirolizumab pegol can convert its Monoclonal antibody profile and CD40L biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Dapirolizumab pegol (query alias: Dapirolizumab pegol) |
|---|---|
| Modality / target | Monoclonal antibody; CD40L; CD40L inhibitors |
| Highest global status | Phase 3 |
| Originator | Biogen, Inc., UCB, Inc. |
| Active developers | Biogen, Inc., UCB Trading (Shanghai) Co., Ltd., UCB Biopharma SRL |
The MCP disease footprint includes Systemic Lupus Erythematosus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04976322 | Phase 3 | Enrolling by invitation | 760 | Incidence of treatment-emergent adverse events (TEAEs) during the study |
| NCT06617325 | Phase 3 | Recruiting | 450 | Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48 |
| EUCTR2019-001967-58-FR | Phase 2 | Completed | 220 | Number of cumulative Gd-enhancing lesions over 2 brain MRI scans at Week 8 and Week 12 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
DAPIROLIZUMAB PEGOL AND FLARE REDUCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN A 48-WEEK PHASE 3 TRIAL: AN UPDATED POST HOC ANALYSIS OF ALTERNATIVE DEFINITIONS OF FLARES THAT REFLECT CLINICAL PRACTICE
Phase 3; n=214; evaluation: Positive. Reported fields: BICLA response = 34.6 % ; BICLA response = 49.5 %
MEASURING FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS: MEASUREMENT PROPERTIES OF THE FATIGUE-PRO TOTAL SCORE USING DATA FROM A PHASE 3 TRIAL OF DAPIROLIZUMAB PEGOL
Phase 3; n=315; evaluation: Positive. Reported fields: Susceptibility to Fatigue(Day 1) = 12.0 point ( 8.0); Susceptibility to Fatigue(Day 1) = 16.0 point ( 9.0)
DAPIROLIZUMAB PEGOL TREATMENT AND IMPROVEMENT IN LABORATORY MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: 48-WEEK RESULTS FROM A PHASE 3 TRIAL
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: BICLA response(Week 48) = 34.6 % ; BICLA response(Week 48) = 49.5 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Dapirolizumab pegol addresses Systemic Lupus Erythematosus. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2018-10-23 | UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
